Physician profile
Armando Beltran
NPI 1649267295
$700.25
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $326 · 2021: $48.64.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $170.55 | 2019-2020 | |
| Novo Nordisk INC | $168.22 | 2019-2020 | |
| Boston Scientific Corporation | $108.71 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $50.40 | 2019 | |
| Abbvie INC. | $48.64 | 2021 | |
| Pfizer INC. | $43.30 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $41.32 | 2019-2020 | |
| Amarin Pharma, INC. | $33.53 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $21.94 | 2019 | |
| Glaxosmithkline, LLC. | $13.64 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Armando Beltran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.